Aristolochic Acid in the Etiology of Renal Cell Carcinoma
暂无分享,去创建一个
K. Kinzler | B. Vogelstein | N. Papadopoulos | Y. Pu | K. Dickman | A. Grollman | Pau-Chung Chen | T. Rosenquist | B. Yun | Chung-Hsin Chen | R. Turesky | Nicholas J. Roberts | M. Hoang
[1] M. Bihoreau,et al. Aristolochic acid exposure in Romania and implications for renal cell carcinoma , 2015, British Journal of Cancer.
[2] D. Lambrechts,et al. Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma , 2015, Nature Medicine.
[3] X. Castells,et al. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid , 2015, International journal of cancer.
[4] Swe Swe Myint,et al. Mutation signatures implicate aristolochic acid in bladder cancer development , 2015, Genome Medicine.
[5] Nansheng Chen,et al. Mutational landscape of intrahepatic cholangiocarcinoma , 2014, Nature Communications.
[6] Hiromi Nakamura,et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.
[7] Edgars Celms,et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe , 2014, Nature Communications.
[8] S. Rorive,et al. Exceptionally long‐term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy , 2014, International journal of cancer.
[9] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[10] P. A. Futreal,et al. Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool , 2013, Science Translational Medicine.
[11] K. Kinzler,et al. Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing , 2013, Science Translational Medicine.
[12] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[13] Boping Zhou,et al. Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma , 2012, Nature Genetics.
[14] C. Iden,et al. Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. , 2012, Chemical research in toxicology.
[15] Arthur P. Grollman,et al. Aristolochic acid-associated urothelial cancer in Taiwan , 2012, Proceedings of the National Academy of Sciences.
[16] B. Jelaković,et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. , 2012, Kidney international.
[17] A. Grollman,et al. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts , 2011, Nucleic acids research.
[18] Huanming Yang,et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.
[19] Shao-Qing Cai,et al. Aristolochic acid nephropathy: variation in presentation and prognosis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] A. Kibel. Population-Based Case–Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer Risk , 2010 .
[21] F. Bob,et al. Therapeutic Remedies Based on Aristolochia clematitis in the Main Foci of Balkan Endemic Nephropathy in Romania , 2010, Nephron Clinical Practice.
[22] Pau-Chung Chen,et al. Population-Based Case–Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer Risk , 2010, Journal of the National Cancer Institute.
[23] J. Scarborough,et al. Chapter 7 Aristolochic Acid Nephropathy: An Environmental and Iatrogenic Disease , 2009 .
[24] Jung-Der Wang,et al. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003 , 2008, Chinese medicine.
[25] F. Debellé,et al. Aristolochic acid nephropathy: a worldwide problem. , 2008, Kidney international.
[26] B. Jelaković,et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy , 2007, Proceedings of the National Academy of Sciences.
[27] A. Grollman,et al. Selective Toxicity of Aristolochic Acids I and II , 2007, Drug Metabolism and Disposition.
[28] H. Schut,et al. Novel LC-ESI/MS/MS(n) method for the characterization and quantification of 2'-deoxyguanosine adducts of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by 2-D linear quadrupole ion trap mass spectrometry. , 2007, Chemical research in toxicology.
[29] Poonam,et al. Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities. , 2003, Natural product reports.
[30] M. Wiessler,et al. Formation and persistence of specific purine DNA adducts by 32P-postlabelling in target and non-target organs of rats treated with aristolochic acid I. , 1993, IARC scientific publications.
[31] J. Simon,et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[32] B. Vogelstein,et al. p53 mutations in human cancers. , 1991, Science.
[33] M. Wiessler,et al. DNA adduct formation of aristolochic acid I and II in vitro and in vivo. , 1988, Carcinogenesis.
[34] P. Carroll,et al. Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. , 1987, Cancer genetics and cytogenetics.